In our previous longitudinal study of t(8;21) AML [16, 17], we discovered a subset of T cells expressing GZMB, NKG7, and GNLY that expanded during the drug-resistant stage, of which the extracted gene signature was shown to be a potential biomarker of prognosis for AML [17]. The gene discussed is GZMB; the disease is acute myeloid leukemia.